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Abstract
Background: Eliminating mother-to-child transmission of HIV (MTCT) in sub-Saharan Africa is hindered by limited
understanding of HIV-testing and HIV-care engagement among pregnant and breastfeeding women.
Methods: We investigated HIV-testing and HIV-care engagement during pregnancy and breastfeeding from 2014
to 2018 in the Agincourt Health and Demographic Surveillance System (HDSS). We linked HIV patient clinic records
to HDSS pregnancy data. We modelled time to a first recorded HIV-diagnosis following conception, and time to
antiretroviral therapy (ART) initiation following diagnosis using Kaplan-Meier methods.
We performed sequence and cluster analyses for all pregnancies linked to HIV-related clinic data to categorise
MTCT risk period engagement patterns and identified factors associated with different engagement patterns using
logistic regression.
We determined factors associated with ART resumption for women who were lost to follow-up (LTFU) using Cox
regression.
Results: Since 2014, 15% of 10,735 pregnancies were recorded as occurring to previously (51%) or newly (49%) HIV-
diagnosed women. New diagnoses increased until 2016 and then declined. We identified four MTCT risk period
engagement patterns (i) early ART/stable care (51.9%), (ii) early ART/unstable care (34.1%), (iii) late ART initiators
(7.6%), and (iv) postnatal seroconversion/early, stable ART (6.4%). Year of delivery, mother’s age, marital status, and
baseline CD4 were associated with these patterns. A new pregnancy increased the likelihood of treatment
resumption following LTFU.
Conclusion: Almost half of all pregnant women did not have optimal ART coverage during the MTCT risk period.
Programmes need to focus on improving retention, and leveraging new pregnancies to re-engage HIV-positive
women on ART.
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Background
In sub-Saharan Africa (SSA) mother-to-child transmis-
sion (MTCT) rates ranged from 1.9% in Botswana to
31.9% in Somalia in 2019 [1]. The risk of MTCT starts
at conception and continues until breastfeeding cessa-
tion, which ranges from 18 to 24months in SSA coun-
tries [2–4]. Without intervention, MTCT risk is
estimated at 5–10% during pregnancy, 10–15% during
delivery, and 5–20% during breastfeeding, with the cu-
mulative risk being 30–45% for infants who are breastfed
for 18–24months [5]. The adoption of Option B+ by
most treatment programmes in SSA, including South
Africa in 2015, has led to large reductions in MTCT
rates [6, 7]. Option B+ has dramatically increased the
number of pregnant women initiating ART, however re-
tention is challenging, particularly in the postnatal
period [8]. Reasons for disengagement include still feel-
ing healthy, transition from PMTCT to adult ART ser-
vices, stigma, and denial of HIV status [9–12]. In 2019,
the United Nations Children’s Emergency Fund
(UNICEF) released their roadmap for the elimination of
mother-to-child transmission of HIV (EMTCT) [13],
which identified missed opportunities for EMTCT in-
cluding failure to prevent seroconversion during preg-
nancy or breastfeeding, mothers living with HIV (MLHI
V) who do not receive antiretroviral therapy (ART),
MLHIV who previously started ART and stopped, and
MLHIV who started ART late in their pregnancy.
An increase in the proportion of people initiating ART
shortly after being diagnosed with HIV, as per World
Health Organisation (WHO) guidance [14], has in turn
led to an increased spectrum of engagement in care pat-
terns, with treatment interruption, reengagement in care
and clinic transfers becoming increasingly prevalent
[15–18]. Previous studies have used cohort and cross-
sectional data to focus on the occurrence of specific
events along the care cascade including linkage to care,
ART initiation, and ART discontinuation [7, 19, 20].
However, these snapshots do not always capture the
complexity of individual care trajectories. Monitoring
these trajectories and understanding the factors that
underlie patterns of disengagement and reengagement in
care is becoming increasingly important to inform inter-
ventions to accelerate progress towards the second and
third targets of the UNAIDS 95–95-95 goals and to re-
duce MTCT [21].
To inform interventions to address missed opportun-
ities for EMTCT, we investigated HIV testing and en-
gagement in care for pregnant and breastfeeding women
in north-eastern South Africa. Using linked demographic
surveillance and health facility data, we report on HIV
testing events, identify periods of ART engagement and
discontinuation during the pregnancy and postpartum
periods for women living with HIV (WLHIV), and
investigate factors associated with ART resumption dur-
ing the MTCT risk period.
Methods
Setting and data sources
The Agincourt Health and Demographic Surveillance
System (HDSS) is approximately 525 km2 with an esti-
mated population of 120,000 residents living in 20,000
households within 31 villages [22]. The HDSS is located
in Mpumalanga province, South Africa with HIV preva-
lence estimated at 14.1% across all ages [22–24]. In
2013, the total fertility rate was estimated as 2.4 children
per woman [25]. Data sources and data used are sum-
marised in Additional file 1.
Demographic surveillance
Fertility, mortality and migration data are collected
annually from residents, based on a comprehensive
household registration system, in operation since 1992
[22, 26]. Fieldworkers visit each household and inter-
view the most knowledgeable adult available to obtain
information on demographic events occurring since
the last census [22, 27, 28]. The HDSS also collects
verbal autopsy data to ascertain probable causes of
death [29, 30]. Wealth quintiles were calculated using
a list of household asset indicators collected as part
of demographic surveillance. These calculations have
been described in more detail elsewhere [30].
Point-of-contact interactive record linkage (PIRL)
Since 2014, HIV patient visits to ART health facilities in
the area have been logged by fieldworkers and linked to
HDSS resident records using Point-of-Contact Inter-
active Record Linkage (PIRL), described in detail else-
where [31, 32]. In brief, a fieldworker conducts a short
uptake interview with patients in the health facility wait-
ing area. Consenting patients are asked for personal
identifiers used to search the HDSS database using a
probabilistic algorithm. Matches are confirmed in inter-
action with the patients, and names of household mem-
bers are used as a key attribute to adjudicate between
possible matches. Linkage data extraction for these ana-
lyses occurred on July 11, 2018.
Record review and patient tracing study
Lost to follow-up (LTFU) data are drawn from a study
described in detail elsewhere [33, 34]. Briefly, on August
15, 2017, all patients within the PIRL database who were
considered LTFU (more than 90 days late for a sched-
uled health facility visit) were recruited into a cohort
and followed up to ascertain whether they were still alive
and on treatment.
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Data preparation and statistical analysis
All pregnancies occurring from 2014 onwards, recorded
in the demographic surveillance database and ending in
a live birth were eligible for this analysis. Women could
contribute more than one pregnancy. Pregnancy data
extraction for these analyses occurred on January 31,
2020, with the last recorded delivery occurring on
November 11, 2018.
The Agincourt HDSS does not routinely conduct HIV
serological surveys among its population. However, the
availability of PIRL data presented a unique opportunity
to update prevalence estimates [35], with linkage to an
HIV-treatment health facility record presumed to indi-
cate an HIV diagnosis. We identified HIV-treatment
health facility records linked to each pregnancy through
the PIRL database to determine dates of HIV diagnosis,
ART initiation, and all HIV-associated health facility
visits. Where no ART initiation date was reported, the
first ART-related health facility visit date was used as
the ART initiation date. Where the HIV diagnosis date
was missing, it was assumed to have occurred the day
before ART initiation (the most common occurrence for
individuals with both HIV diagnosis and ART initiation
dates available in our data). Conception for each preg-
nancy was estimated to have occurred 280 days prior to
the delivery date. Demographic and health surveys data
suggests that 10% of babies were still breastfed at 23
months in South Africa in 2016 [36], therefore, breast-
feeding cessation was set at 24 months (730 days) follow-
ing the delivery date to give the longest possible period
of transmission risk.
Seroconversions and ART initiation
Any pregnancy for which an HIV diagnosis date oc-
curred before the conception date was excluded from
seroconversion analyses. Time to a first recorded HIV-
positive result was calculated with the estimated concep-
tion date as the origin. We also calculated time to ART
initiation with the date of the first recorded HIV-
positive result as the origin. These time-to-event data
were modelled using Kaplan-Meier methods.
Sequence states and outcomes
All pregnancies for which a first HIV-positive result was
recorded before breastfeeding cessation were considered
for this analysis. Each pregnancy was assigned a 1010-
day sequence corresponding to 280 days of pregnancy
and 730 days of breastfeeding. There were nine possible
sequence states (Table 1).
Using a state sequence-analysis approach, and utilising
Optimal Matching distances, we identified distinct clus-
ters of sequences with similar patterns of engagement in
care during the MTCT risk period. Using logistic regres-
sion, we determined factors associated with belonging to
a given cluster, after multiple imputation to account for
missingness in the explanatory variables.
Factors associated with ART resumption
Using the record review and tracing study data, we re-
stricted these analyses to women of reproductive age
who were considered LTFU. Resumption of ART was
defined as either reengagement or transfer, following
loss to follow-up. Follow-up time began on the date of
each patient’s last recorded clinic visit. Follow-up time
was split into monthly intervals to account for preg-
nancy which was included as a time-varying covariate.
We linked pregnancy data from the HDSS to identify
new pregnancies, defined as a pregnancy occurring after
LTFU that was not associated with previous HIV-
treatment episodes. Women were considered pregnant if
a monthly interval fell within the period of a new preg-
nancy identified through HDSS data. All other covariates
remained constant in each time interval. A Cox regres-
sion model was used to determine the factors associated
with ART resumption, with all other outcomes consid-
ered to be right-censored. Bi-variate analyses were con-
ducted with a priori selected variables for which there
was a plausible association to ART resumption. All vari-
ables with p < 0.1 were included in the multivariable Cox
Table 1 Definitions of all the possible sequence states
State Definition
Unknown HIV No health facility records of an HIV diagnosis, or ART initiation before the pregnancy or breastfeeding period.
HIV+ no ART Following HIV diagnosis, ART not initiated, or ART initiated but without any follow-up visits immediately following ART initiation.
On ART At least one health facility visit following the ART initiation visit. Women remained on ART up to their next scheduled visit.
Late Between 7 and 90 days late for a scheduled health facility visit following ART initiation.
LTFU More than 90 days late for a scheduled health facility visit following ART initiation.
Deceased From the date of death extracted from HDSS records.
Transferred A record of treatment collection from a health facility within the Agincourt HDSS other than where ART initiation occurred.
Reengaged Restarted treatment at the same health facility where ART initiation occurred following LTFU.
Migration Out migrated from the HDSS with no evidence of health facility visits following the migration date.
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regression model. A parsimonious model was achieved
using Wald tests. All models accounted for clustering at
the clinic level and utilised robust standard errors.
Sequence analyses were conducted using the
TraMineR R-package [37]. All other analyses were
conducted using Stata 16 [38].
Results
Population characteristics
Between January 2014 and November 2018, 10,102
women had 10,831 pregnancies recorded in the HDSS,
among which 96 (0.9%) ended in a still birth or abortion.
The remaining 10,735 live births were recorded for
10,035 women (Table 2). Median age at delivery was 26
years (IQR: 21, 32).
Seroconversions and ART initiation
Of the 10,735 pregnancies ending in live births, 1628
(15.2%) were linked to an HIV-related health facility rec-
ord. Of these, 823 (50.6%) had a first HIV-positive test
recorded before the estimated conception date and were
excluded from Kaplan-Meier (KM) models, 585 (35.9%)
had a first test recorded during the pregnancy, 127
(7.8%) had a first test recorded during the breastfeeding
period, and 93 (5.7%) had a first test occurring after
breastfeeding cessation.
For women contributing more than one pregnancy to
the analysis, previous pregnancies contributed analysis
time up to the estimated conception date of the next
pregnancy. The cumulative probability of having a posi-
tive HIV test by the end of the most recent pregnancy
was 5.95, and 7.47% by the end of breastfeeding. The
probability of having an HIV positive test varied by year
of delivery (with a 1.5% reduction between 2016 and
2017 (p = 0.0201)) (Fig. 1), was higher for older women
peaking in the 30–34 age group, for women in lower
wealth quintiles, for divorced or widowed women, and
for less educated women (all p < 0.001).
The cumulative probability of ART initiation following
a recorded HIV-positive test during pregnancy was
50.59% after 43 days, 75.04% after 202 days, 90.15% after
547 days, and 100% after 1687 days. This probability
increased by year of delivery with a significant reduction
in initiation time from 2016 (< 0.001) (Additional file 2).
Engagement sequences and clusters
We identified distinct patterns of clinic attendance
connected to the pregnancy and breastfeeding period
(Additional file 3), with 1477 women contributing 1628
pregnancies which were treated as independent for the
purpose of this analysis. Of 1628 pregnant women, 93
were excluded from these analyses because the first
recorded HIV positive test occurred after the breastfeed-
ing period.
Of the remaining 1535 pregnant women, 710
(46.3%) had an unknown HIV status, 258 (16.8%)
were HIV-positive but not on ART, 344 (22.4%)
were on ART, 58 (3.8%) were late for their most re-
cent appointment, and 165 (10.7%) were LTFU from
HIV care at the beginning of their pregnancy. There
was a yearly increase in the proportion of women
already on ART at the beginning of their pregnancy
starting at 0% in 2014 and increasing to 39.25% by
2018 (p < 0.001). Of 258 WLHIV but not on ART
when they became pregnant, 133 (51.5%) had not
initiated ART at delivery. Of 165 WLHIV who were
LTFU when they became pregnant, 109 (66.1%) were
still LTFU at delivery, however, 148 (89.7%) resumed
ART by the end of the breastfeeding period (Fig. 2).
The highest resumption happened in the 6 months
leading up to delivery (33 (20.0%) second trimester, 28
(17%) third trimester), was its lowest in the 3 months
after delivery (17 (10.3%) pregnant women) and in-
creased during the breastfeeding period before levelling
off (Additional file 4).
Cluster analysis identified four distinct patterns of
engagement in care in the MTCT risk period: (i)
women who initiated ART early and were stable in
care (n = 796, 51.9%), (ii) women who initiated ART
early but were not stable in care (characterised by
frequent ART stoppages or late appointment attend-
ance) (n = 524, 34.1%), (iii) women who were late
ART initiators (n = 117, 7.6%), and (iv) postnatal
seroconversion with early, stable ART (n = 98, 6.4%).
In the logistic regression model, older women and
women who delivered more recently were more
likely to be in the early stable ART group. Younger
women were more likely to seroconvert postnatally.
Women who delivered in 2015 and 2016 were least
likely to be in the late ART group or to seroconvert
postnatally. Married women and women with a base-
line CD4 > 500 cells/ μL were more likely to initiate
ART late. (Additional file 5).
Factors associated with ART resumption
Of 767 (75.4%) women recorded as LTFU in the PIRL
database, 62 (8.1%) were older than reproductive age
(> 51 years) and were excluded from this analysis. Of
the remaining 705, 279 (39.6%) initiated ART for
PMTCT, 354 (50.2%) had been LTFU for less than a
year, 468 (66.4%) had a baseline CD4 > 200 cells/ μL,
and 84 (11.9%) had a pregnancy occurring during the
follow-up time. The median age was 31 years (IQR:
27, 36) (Table 3).
Of these 705 women, 247 (35.0%) were found to
have resumed ART (147 (59.5%) reengaged and 100
(40.5%) transferred). Women were out of care a me-
dian of 312 days (IQR: 182, 541) before resuming
Etoori et al. BMC Public Health         (2021) 21:1710 Page 4 of 12


















Pregnancies 9107 (84.8) 823 (7.7) 585 (5.4) 127 (1.2) 93 (0.9) 10,735
Delivery year
2014 2248 (83.9) 154 (5.8) 156 (5.8) 53 (2.0) 67 (2.5) 2673
2015 2046 (84.4) 167 (6.9) 145 (6.0) 39 (1.6) 26 (1.1) 2423
2016 1888 (84.6) 182 (8.2) 139 (6.2) 23 (1.0) 0 (0) 2232
2017 1749 (85.7) 185 (9.1) 94 (4.6) 12 (0.6) 0 (0) 2040
2018 1176 (86.3) 135 (9.9) 51 (3.7) 0 (0) 0 (0) 1362
Age group
10–14 32 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 32
15–19 1663 (95.0) 20 (1.1) 33 (1.9) 18 (1.0) 17 (1.0) 1751
20–24 2517 (89.8) 96 (3.4) 132 (4.7) 32 (1.1) 27 (1.0) 2804
25–29 2244 (84.0) 185 (6.9) 184 (6.9) 34 (1.3) 24 (0.9) 2671
30–34 1517 (78.0) 244 (12.5) 141 (7.2) 26 (1.3) 17 (0.9) 1945
35–39 804 (73.4) 202 (18.4) 72 (6.6) 10 (0.9) 7 (0.6) 1095
40+ 330 (75.5) 76 (17.4) 23 (5.3) 7 (1.6) 1 (0.2) 437
Gravida
1 6462 (88.9) 315 (4.3) 345 (4.7) 83 (1.1) 61 (0.8) 7266
2 1961 (78.3) 318 (12.7) 171 (6.8) 29 (1.2) 26 (1.0) 2505
3 474 (71.2) 135 (20.3) 47 (7.1) 8 (1.2) 2 (0.3) 666
4 133 (66.5) 41 (20.5) 17 (8.5) 6 (3.0) 3 (1.5) 200
5 45 (71.4) 11 (17.5) 5 (7.9) 1 (1.6) 1 (1.6) 63
6 24 (88.9) 3 (11.1) 0 (0) 0 (0) 0 (0) 27
7 6 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 6
8 2 (100.0) 0 (0) 0 (0) 0 (0) 0 (0) 2
Planned pregnancy
No 4170 (85.2) 357 (7.3) 258 (5.3) 65 (1.3) 44 (0.9) 4894
Yes 3998 (83.7) 398 (8.3) 282 (5.9) 53 (1.1) 46 (1.0) 4777
Missing 939 (88.3) 68 (6.4) 45 (4.2) 9 (0.8) 3 (0.3) 1064
Education
No formal education 97 (76.4) 15 (11.8) 9 (7.1) 4 (3.1) 2 (1.6) 127
Primary 1289 (79.2) 172 (10.6) 118 (7.2) 28 (1.7) 21 (1.3) 1628
Secondary 6303 (85.8) 524 (7.1) 385 (5.2) 77 (1.0) 56 (0.8) 7345
Tertiary 599 (92.7) 21 (3.3) 22 (3.4) 3 (0.5) 1 (0.2) 646
Missing 819 (82.8) 91 (9.2) 51 (5.2) 15 (1.5) 13 (1.3) 989
Marital status
Single 5902 (85.4) 492 (7.1) 369 (5.3) 89 (1.3) 58 (0.8) 6910
Married 1312 (88.8) 91 (6.2) 56 (3.8) 11 (0.7) 8 (0.5) 1478
Informal union 1390 (84.2) 129 (7.8) 98 (5.9) 16 (1.0) 18 (1.1) 1651
Separated 359 (77.9) 57 (12.4) 33 (7.2) 4 (0.9) 8 (1.7) 461
Divorced 78 (60.9) 28 (21.9) 17 (13.3) 4 (3.1) 1 (0.8) 128
Widowed 66 (61.7) 26 (24.3) 12 (11.2) 3 (2.8) 0 (0) 107
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ART (Reengaged: 333 (170, 525), Transferred: 297.5
(185, 563), p = 0.6482). In the multivariable Cox
model, a new pregnancy was associated with ART re-
sumption (aHR: 2.79, 95% C.I: 1.31, 5.95) when com-
pared to women who did not have a pregnancy
occurring during the follow-up time. Longer time on
ART before LTFU, higher baseline CD4, initiating
ART after 2015, and being on a longer refill schedule
(a proxy for stable patients) were associated with a
higher hazard of ART resumption following LTFU.
The hazard of ART resumption was lower the longer
a patient had been LTFU (Table 3).
Discussion
Using linked demographic surveillance and health facil-
ity data, we investigated patterns of HIV testing and en-
gagement in care for pregnant and breastfeeding
women. Our findings showed a reduction in the number
of women testing positive each year during the MTCT
risk period. We also identified four patterns of engage-
ment in care during the MTCT risk period representing
varying times of seroconversion and different levels of
care stability following ART initiation, with women’s
age, marital status, baseline CD4 and the year of delivery
predicting these patterns. We also found that following



















1 1369 (82.2) 156 (9.4) 103 (6.2) 25 (1.5) 12 (0.7) 1665
2 1607 (82.4) 167 (8.6) 130 (6.7) 26 (1.3) 21 (1.1) 1951
3 1715 (85.0) 150 (7.4) 105 (5.2) 24 (1.2) 24 (1.2) 2018
4 1895 (85.2) 167 (7.5) 117 (5.3) 25 (1.1) 21 (0.9) 2225
5 1967 (88.2) 135 (6.1) 98 (4.4) 20 (0.9) 10 (0.4) 2230
Missing 554 (85.8) 48 (7.4) 32 (5.0) 7 (1.1) 5 (0.8) 646
Fig. 1 Kaplan-Meier curves showing the probability of an HIV-positive test during the vertical transmission risk period stratified by the year
of delivery. This figure shows the cumulatative probability of having an HIV positive test linked to a pregnant or postpartum woman given there
was no previous record or evidence of HIV diagnosis or clinic attendance for HIV care. This cumulative probability is stratified by delivery year
showing a reduction in the cumulative probability in 2017 and 2018
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discontinuation of HIV care, ART resumption was more
likely for women who had a new pregnancy.
An estimated 15% of pregnancies resulting in a live
birth recorded in the Agincourt HDSS were to women
who had utilised HIV-related healthcare. Of the preg-
nancies linked to HIV-related healthcare utilisation, 51%
were to previously diagnosed women and 49% had no
previous HIV-related healthcare data and were pre-
sumed to be new diagnoses. Although some of the
women who were previously diagnosed had disengaged
from care, encouragingly most resumed treatment over
the study period.
Reengagement in care is becoming a more common
phenomenon as more healthy patients initiate ART [15].
Our finding that a new pregnancy was associated with
an increased probability of resumption was probably due
to increased interaction with the health system, as well
as a desire to protect their baby. Whilst about half of
these women resumed ART before delivery, research
shows that ART initiation early in the pregnancy is most
effective at reducing MTCT risk [14, 39]. Furthermore,
whilst ART resumption is a positive outcome, it repre-
sents a programmatic failure of Option B+ which aims
to keep women on ART for life and extend protection
throughout subsequent pregnancies. Treatment inter-
ruptions may also contribute to drug resistance [40, 41].
We found that 66.1% of WLHIV who were LTFU when
they became pregnant and 51.5% of WLHIV but not on
ART when they became pregnant were still not on treat-
ment by delivery, indicating that ART programmes still
have much work to do to initiate and keep less compli-
ant patients on ART.
The cumulative probability of a new HIV diagnosis oc-
curring during the MTCT risk period was estimated as
5.9% during pregnancy, increasing to 7.5% by the breast-
feeding cessation. The proportion of women testing
positive for HIV during pregnancy increased until 2016,
reaching 7%, and then declined in 2017 to 5%. These are
likely to be underestimates as some women might have
attended private facilities or facilities outside the HDSS.
Additionally, while UNAIDS estimated that 90.1% of
pregnant women in South Africa were tested for HIV in
2019 [1], without a comprehensive HIV testing database
where both negative and positive results are recorded, it
is likely that not all seroconversions were captured.
Nonetheless, the reduction in the number of women
testing HIV positive in 2017 is encouraging. Option B+
and treat all were implemented as part of the paradigm
Fig. 2 Chronograms of engagement in care during the vertical risk transmission period by status at the beginning of the pregnancy
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Table 3 Factors associated with resumption of ART following loss to follow-up
LTFU HR (95% CI) p-value aHR (95% CI) p-value
705
N (%)
Pregnancy during follow-up time
No 621 (88.1) Reference __ Reference __
Yes 84 (11.9) 2.85 (1.50, 5.43) 0.001 2.79 (1.31, 5.95) 0.008
Age
18–24 117 (16.6) 0.81 (0.44, 1.50) 0.511
25–34 379 (53.8) Reference __
35–44 161 (22.8) 1.01 (0.78, 1.31) 0.927
45–51 48 (6.8) 0.88 (0.62, 1.24) 0.462
ART reason
Non-PMTCT 426 (60.4) Reference __
PMTCT 279 (39.6) 0.78 (0.66, 0.92) 0.003
ART start year
2014 144 (20.4) 1.18 (0.69, 1.99) 0.545 0.88 (0.48, 1.63) 0.69
2015 288 (40.8) Reference __ Reference __
2016 248 (35.2) 1.36 (1.07, 1.71) 0.011 2.17 (1.28, 3.67) 0.004
2017 25 (3.6) 1.38 (0.72, 2.64) 0.324 3.08 (1.07, 8.84) 0.037
Time on ART
≤ 3 months 208 (29.5) Reference __ Reference __
3–6 months 150 (21.3) 0.90 (0.61, 1.33) 0.599 1.06 (0.71, 1.58) 0.78
6–12 months 174 (24.7) 1.70 (1.09, 2.65) 0.018 1.98 (1.20, 3.26) 0.008
12–24months 139 (19.7) 3.29 (1.44, 7.51) 0.005 4.43 (1.66, 11.84) 0.003
> 24 months 34 (4.8) 5.73 (3.60, 9.10) < 0.001 7.90 (3.56, 17.51) < 0.001
Baseline CD4
< 100 105 (15.4) 0.67 (0.34, 1.32) 0.244 0.76 (0.37, 1.59) 0.474
100–199 107 (15.7) 0.82 (0.62, 1.08) 0.152 0.87 (0.62, 1.22) 0.416
200–349 183 (26.9) Reference __ Reference __
350–499 159 (23.4) 0.90 (0.68, 1.19) 0.461 1.17 (0.82, 1.67) 0.395
500+ 126 (18.5) 1.48 (1.01, 2.17) 0.044 1.76 (1.40, 2.20) < 0.001
Baseline WHO stage
I 554 (79.6) Reference __
II 75 (10.8) 1.27 (0.93, 1.73) 0.136
III 62 (8.9) 1.29 (0.60, 2.74) 0.512
IV 5 (0.7) 0.91 (0.24, 3.43) 0.885
Refill schedule
1 month 469 (66.5) Reference __ Reference __
2months 157 (22.3) 0.93 (0.56, 1.56) 0.791 0.86 (0.47, 1.60) 0.646
3 months 60 (8.5) 1.29 (0.94, 1.78) 0.112 0.88 (0.54, 1.44) 0.604
> 3months 19 (2.7) 6.42 (4.24, 9.73) < 0.001 2.79 (2.11, 3.69) < 0.001
Health Facility
Agincourt 195 (27.7) Reference __ Reference __
Belfast 135 (19.2) 0.36 (0.34, 0.39) < 0.001 0.48 (0.41, 0.57) < 0.001
Cunningmore 44 (6.2) 0.37 (0.35, 0.40) < 0.001 0.65 (0.53, 0.80) 0.001
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shift towards using treatment as prevention. South Af-
rica national guidelines moved to Option B+ in 2015
and to universal treatment in 2016 [6, 42], all of which
have been widely adopted in the area covered by the
Agincourt HDSS. Other countries have reported a surge
in the volume of pregnant women testing positive and
utilising PMTCT services as more women became eli-
gible for ART following the implementation of Option
B+ [43]. This was followed by a steady decline as more
WLHIV became aware of their HIV status [44]. Our data
suggests, there was a further reduction in 2018, however,
further research and monitoring of this trend will be
needed.
Over half of HIV-exposed pregnancies occurred to
women who already knew their HIV status. There is a
general recognition that the number of HIV-positive
women having children who already know their HIV-
status is increasing [44, 45], illustrating the importance
of keeping women engaged in care and virally sup-
pressed. Our finding that older age was associated with
sustained retention on ART aligns with other studies
[46–49]. Later year of delivery was also found to be asso-
ciated with early stable ART with the odds of late ART
decreasing over time potentially showing the benefits of
simplified treatment guidelines under Option B+. We
found that married women were more likely to initiate
ART late which other studies have reported citing the
need for their partner’s support [50–52]. As such, inter-
ventions that improve partner support such as couple
testing or joint counselling are important to encourage
early ART initiation for married women [10, 53, 54].
Teenage mothers were more likely to have a first posi-
tive test recorded postnatally which might suggest late
seroconversion, late testing, or poorer health seeking be-
haviour, all of which have been reported as important
factors among this age group in similar settings [55–57].
Older women were more likely to have already serocon-
verted or to be on treatment at the beginning of their
pregnancy which possibly reflects their longer time at
risk for HIV. There were lower odds of postnatal
seroconversion in later years, possibly indicating reduced
incidence of HIV in the wider population.
This study has some limitations. Firstly, the health fa-
cilities used may not capture every sentinel event as a
small proportion of HDSS residents receive ART
through private facilities or public facilities outside the
HDSS. Furthermore, we did not have treatment adher-
ence data. The assumption that a patient was in care
until their next scheduled visit might therefore misclas-
sify some patients. During the linkage process a very
small proportion of residents declined to be linked and
we did not manage to link everyone that claimed to be
an HDSS resident. These linkage errors might bias these
results downwards. Finally, there are biases arising from
using routinely collected data. If women testing positive
did not self-report a previous diagnosis, we would have
erroneously categorised them as newly diagnosed. Add-
itionally, if a woman tested positive but did not report to
the PMTCT clinic to start treatment then she would
have been missed as this data would only be available in
the testing registers which were not linked to HDSS
data. Finally, data from 2018 does not include clinic data
past July 2018 or pregnancy data past November 2018,
as such HIV incidence reduction seen in our analysis in
2018 might be an effect of the data.
This study also has some strengths. To our knowledge,
this is the first study to use linkage of population and
clinical records to estimate HIV incidence in pregnant
women in SSA. The method of linking routinely col-
lected data to answer this question shows promise and
should be considered in future research. The use of mul-
tiple data sources also means we were able to crosscheck
matching data and had access to new pregnancies data
and socioeconomic variables which are not always avail-
able in clinical data.
Conclusions
In conclusion, our study shows the importance of new
pregnancies in encouraging treatment resumption for
women previously LTFU. This coupled with the
Table 3 Factors associated with resumption of ART following loss to follow-up (Continued)
LTFU HR (95% CI) p-value aHR (95% CI) p-value
Justicia 75 (10.6) 0.32 (0.28, 0.36) < 0.001 0.53 (0.45, 0.61) < 0.001
Kildare 75 (10.6) 0.84 (0.83, 0.86) < 0.001 0.96 (0.73, 1.27) 0.804
Lillydale 110 (15.6) 0.65 (0.62, 0.68) < 0.001 1.01 (0.88, 1.16) 0.854
Thulamahashe 21 (3.0) 0.64 (0.63, 0.65) < 0.001 0.67 (0.56, 0.81) < 0.001
Xanthia 50 (7.1) 0.60 (0.59, 0.61) < 0.001 0.59 (0.45, 0.76) < 0.001
Time since last appointment
≤ 1 year 354 (50.2) Reference __ Reference __
1–2 years 269 (38.2) 0.36 (0.28, 0.46) < 0.001 0.63 (0.49, 0.80) < 0.001
> 2 years 82 (11.6) 0.10 (0.06, 0.17) < 0.001 0.33 (0.16, 0.65) 0.001
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reduction in the number and proportion of pregnant
and postpartum women testing HIV positive should be
considered as successes of the Option B+ programme.
Our study also shows the growing scale of reengagement
in care. Treatment programmes will need interventions
to keep pregnant women on ART after delivery and en-
sure that pregnant women previously in care are reen-
gaged promptly for their own health and to protect their
unborn infants.
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